Aethlon Medical (AEMD)

Executive Summary

Aethlon Medical is a San Diego-based medical device company focused on the Aethlon Hemopurifier®, a first-in-class technology designed to rapidly deplete cancer-promoting exosomes and circulating viruses. The Hemopurifier has received FDA Breakthrough Device designation for use in advanced or metastatic cancer patients who are unresponsive to or intolerant of standard therapies, as well as for certain infectious diseases. The company's platform addresses significant unmet needs in oncology and virology by targeting extracellular vesicles and pathogens that contribute to disease progression and treatment resistance. Despite its innovative approach, Aethlon Medical is a small-cap company with limited commercialization to date, relying on clinical validation and regulatory milestones to drive value. The stock trades under ticker AEMD and has a modest market capitalization, reflecting the early-stage nature of its technology and the high risk associated with development-stage medical devices. Aethlon's near-term prospects hinge on advancing its clinical programs and securing regulatory approvals. The company is pursuing multiple indications, including solid tumors and viral infections, with the Hemopurifier's unique mechanism offering potential synergies in combination with immunotherapies. However, financial constraints and the need for larger clinical trials present challenges. Key upcoming catalysts include updates on FDA interactions for its cancer program, potential trial data in infectious disease, and possible strategic partnerships to fund development. The company's success will depend on its ability to demonstrate clinical efficacy, navigate regulatory pathways, and secure sufficient capital to scale operations.

Upcoming Catalysts (preview)

• Q3 2026FDA Feedback or Clearance for Cancer Indication60% success
• Q4 2026Clinical Trial Results for Infectious Disease Application40% success
• Q2 2026Strategic Partnership or Licensing Deal30% success